Yes, Methotrexate Causes Birth Defects
Methotrexate, a folate antagonist used for rheumatoid arthritis, cancer, and ectopic pregnancies, disrupts DNA synthesis and cell division, leading to high risks of congenital malformations when taken during pregnancy. Exposure in the first trimester causes defects in up to 20-30% of cases, including craniofacial dysmorphism (e.g., hypertelorism, micrognathia), limb abnormalities (e.g., syndactyly, clubfoot), and growth restriction—known as methotrexate embryopathy.[1][2]
How Does Methotrexate Affect a Developing Fetus?
It inhibits dihydrofolate reductase, blocking folic acid conversion to tetrahydrofolate, which impairs purine and pyrimidine synthesis essential for fetal organ formation. Peak sensitivity occurs 6-8 weeks post-conception during neural tube and limb bud development. Even low doses (7.5-25 mg/week) pose risks; animal studies confirm dose-dependent teratogenicity.[3][4]
What If Taken Before Knowing About Pregnancy?
Preconception or early undiagnosed pregnancy exposure (first 4-6 weeks) still risks miscarriage (up to 45%) or defects, though less severe than later first-trimester use. Folate supplementation does not fully mitigate effects due to methotrexate's direct antagonism.[1][5]
Safe Timing for Pregnancy After Stopping Methotrexate?
Guidelines recommend waiting 3-6 months post-discontinuation before conceiving, allowing drug clearance (half-life ~3-10 hours, but metabolites persist). Rheumatology societies like ACR and EULAR advise 3 months for men and women; some extend to 6 months for caution.[2][6]
Who Is Most at Risk?
Women of childbearing potential on methotrexate must use reliable contraception. Risks rise with higher cumulative doses (>10 mg/week) or combination therapy. Paternal exposure shows minimal evidence of harm, but sperm DNA effects are under study.[4][7]
Alternatives During Pregnancy Planning
Switch to safer options like sulfasalazine, hydroxychloroquine, or biologics (e.g., etanercept) for rheumatoid arthritis. For psoriasis or cancer, consult specialists for non-teratogenic regimens. Folic acid (5 mg/day) is standard but insufficient alone with methotrexate.[6][8]
[1] CDC: Methotrexate Teratogenicity
[2] ACR Guidelines on Pregnancy and Rheumatic Disease
[3] FDA Label: Methotrexate
[4] PubMed: Methotrexate Embryopathy Review
[5] EULAR Recommendations
[6] MotherToBaby Fact Sheet
[7] Reproductive Toxicology Journal
[8] UpToDate: Drug Safety in Pregnancy